Anondita Medicare Capital Structure Change
Anondita Medicare Limited has reinstated its previous rights issue corrigendum. The issue size is now confirmed at 9,58,166 equity shares, aggregating to ₹91.03 Crore.
- Value
- ₹91.03 Cr
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
59 announcements with these filters
Anondita Medicare Limited has reinstated its previous rights issue corrigendum. The issue size is now confirmed at 9,58,166 equity shares, aggregating to ₹91.03 Crore.
Anondita Medicare Limited issued a corrigendum to its Rights Issue, revising the total issue size to ₹91.03 Crore and adjusting the allocation for general corporate purposes.
Anondita Medicare Limited clarified procedures for handling odd lots of Rights Entitlements and shares during its ongoing Rights Issue. No new transaction value is involved.
Anondita Medicare Limited has issued the notice for its 3rd Annual General Meeting scheduled for September 29, 2026. The meeting will address ordinary and special business resolutions.
Anondita Medicare Limited has been declared the L1 bidder by the Central Medical Services Society for supplying 8.01 crore pieces of condoms.
Anondita Medicare Limited announced a Rights Issue of 9.58 lakh equity shares to raise up to ₹91.01 Crore. The issue opens on September 9, 2026.
Anondita Medicare Limited has appointed M/s Mohit Singhal & Associates as the Secretarial Auditor for the financial year 2026-2027. This is a routine secretarial appointment.
Anondita Medicare Limited has fixed September 02, 2026, as the record date for determining shareholders eligible for its Rights Issue of Equity Shares.
Anondita Medicare Limited approved a rights issue of 9,58,000 equity shares at an issue price of ₹950 per share.
Anondita Medicare Limited received in-principle approval from NSE for a proposed Rights Issue. The issue aggregates up to ₹109.78 Crore at a face value of ₹10 per share.
Anondita Medicare Limited has deferred its board meeting scheduled for August 7, 2026. The delay is due to pending in-principle approval from the NSE for a rights issue.
Anondita Medicare Limited's board approved a rights issue of equity shares for an aggregate amount not exceeding ₹109.78 Crore. The terms will be determined later.
Anondita Medicare Limited has scheduled a board meeting for August 1, 2026, to discuss potential fundraising via a rights issue.
Anondita Medicare Limited issued a corporate guarantee of ₹5 Crore in favor of HDFC Bank for its subsidiary, Anondita Healthcare and Rubber Products India Limited.
Anondita Medicare clarified clerical EPS errors in its FY26 financial results following an NSE query. The company confirmed compliance regarding monitoring agency reports for issue proceeds.
Anondita Medicare Ltd issued 285,000 convertible preferential shares at ₹1,038 each, raising approximately ₹29.58 Crore. The issue increased paid‑up capital to ₹183.72 Crore, with the promoter as sole investor.
Anondita Medicare allotted 2,85,000 convertible warrants at Rs.1,038 each to a promoter. The transaction totals Rs.29.58 Crore with an 18-month conversion period.
Anondita Medicare received NSE in-principle approval to issue 2.85 lakh convertible warrants at Rs. 1,038 each. The Rs. 29.58 Crore preferential issuance targets the promoter category.
Anondita Medicare Ltd reported revenue from operations of ₹54.1 Cr (+72.3% YoY) and net profit of ₹13 Cr (+116.7% YoY) for H1 FY26.
Anondita Medicare submitted the machine-readable auditor's report for standalone and consolidated financial results. The report covers the period ending March 31, 2026.
Anondita Medicare Limited (ANONDITA) reports FY26 revenue of ₹13,741.57 Cr with 37.5% EBITDA margins. The company is scaling capacity and expanding internationally across Brazil and South Africa.
Anondita Medicare reported strong FY26 results with revenue growing 78% YoY to ₹137.42cr and PAT rising 107% to ₹34.30cr. Strategy focuses on high-margin female condoms and international market expansion.
Anondita Medicare Limited approved an amendment to its Memorandum of Association's main object clause. The expanded scope includes sexual wellness, personal care, and healthcare products.
Anondita Medicare Limited announced the successful passing of seven resolutions at its EGM. Approved items include warrant issuance, related party transactions, and managerial remuneration increases.
Anondita Medicare secured a Rs. 43.14 Crore export order from Supra Healthcare for supplying 50 containers of condoms. The contract, expiring September 2026, marks its South African market entry.
Anondita Medicare Ltd reported revenue from operations of ₹83.3 Cr and net profit of ₹21.3 Cr for H2 FY26.
Anondita Medicare reported a consolidated total income of ₹138.26 Crore for FY2026. The company achieved a consolidated net profit of ₹34.30 Crore during the period.
Anondita Medicare secured a ₹0.04 Crore international order from S.S.R Traders for condom supplies. The contract features a 4-6 week execution period from advance receipt.
Anondita Medicare Limited re-submitted audited financial results to rectify clerical errors in profit allocation and EPS. Reported net profit and overall financial position remain unchanged.
Anondita Medicare secured a massive ₹5,16,024 Crore condom supply order from Nepal's Lotus Pharmaceuticals. Delivery is scheduled within six weeks of advance payment.